[6-K] Haleon plc American Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Haleon plc reports the purchase and cancellation of 354,000 ordinary shares of
each under the second tranche of its share buyback programme announced 31 July 2025. Following settlement, registered share capital is 8,955,967,411 ordinary shares, of which 3,880,205 are held as treasury shares, leaving 8,952,087,206 ordinary shares with voting rights. The announcement notes the trade venue (London Stock Exchange CBOE (UK)/CXE) and provides a link to a full breakdown of individual trades. The company also states this is not an offer for securities and that details are available on its investor website.

Positive

• Buyback executed: Company completed purchase and cancellation of 354,000 ordinary shares under its announced programme.
• Updated capital figures: Provides precise post-transaction counts: 8,955,967,411 registered shares; 3,880,205 treasury shares; 8,952,087,206 voting shares.
• Regulatory transparency: Includes trade venue and link to full individual trade breakdown complying with Market Abuse Regulation disclosure requirements.

Negative

• None.

Insights

Financial Analyst

TL;DR: Small executed share buyback slightly reduces shares outstanding and provides updated voting share count.

The report documents a completed purchase and cancellation of 354,000 ordinary shares under the previously announced buyback programme. This reduces the company's registered shares and adjusts the number of voting shares to 8,952,087,206, a useful operational figure for disclosure thresholds under UK rules. The disclosure includes venue and a link to the trade breakdown, meeting market transparency requirements. The transaction size is modest relative to total shares outstanding and is a routine capital-return activity rather than a material corporate event.

Corporate Governance Expert

TL;DR: Proper regulatory disclosure of buyback execution and updated voting share count; no governance red flags apparent.

The Form 6-K supplies the required market abuse regulation trade breakdown link and confirms cancellation of shares, which affects the company's issued capital and treasury holdings. The announcement clarifies the voting-share figure that shareholders must use for disclosure obligations. There is no indication of executive changes, litigation, or other governance actions in this notice; it reads as compliant, routine disclosure.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2025

Commission File Number: 001-41411

Haleon plc

(Translation of registrant’s name into English)

Building 5, First Floor, The Heights,

Weybridge, Surrey, KT13 0NY

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

Exhibit Number	Description
99.1	04 September 2025 - “Transaction in Own Shares”

99.1

Haleon plc: Transaction in own shares

04 September 2025: Haleon plc (the "Company" or "Haleon") today announces the purchase of 354,000 ordinary shares of £0.01 each in the Company (the "Shares") for cancellation under the second tranche of its share buyback programme announced on 31 July 2025.

	London Stock Exchange	CBOE (UK)/BXE	CBOE (UK)/CXE
Date of purchase:	03 September 2025	03 September 2025	03 September 2025
Number of Shares purchased:	354,000	-	-
Highest price paid per Share (p):	370.3000	-	-
Lowest price paid per Share (p):	363.4000	-	-
Volume weighted average price paid per Share (p):	366.1277	-	-

Following the settlement of the above, the Company's registered share capital is 8,955,967,411 ordinary shares of £0.01 each, of which 3,880,205 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,952,087,206 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:

http://www.rns-pdf.londonstockexchange.com/rns/9239X_1-2025-9-3.pdf

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.

Enquiries
Investors		Media
Jo Russell	+44 7787 392441	Zoë Bird	+44 7736 746167
Rakesh Patel	+44 7552 484646	Victoria Durman	+44 7894 505730
Email: investor-relations@haleon.com		Email: corporate.media@haleon.com

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com. 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		HALEON PLC (Registrant)
Date: September 04, 2025	By:	/s/ Amanda Mellor
		Name:	Amanda Mellor
		Title:	Company Secretary

FAQ

What share buyback did Haleon (HLN) report on 04 September 2025?

Haleon reported the purchase and cancellation of 354,000 ordinary shares under the second tranche of its buyback programme.

How many Haleon shares are outstanding with voting rights after the transaction?

After settlement the number of ordinary shares with voting rights is 8,952,087,206.

Where can I find the detailed breakdown of the individual trades?

The announcement provides a link to the trade breakdown at http://www.rns-pdf.londonstockexchange.com/rns/9239X_1-2025-9-3.pdf and on Haleon's investor website.

Does this announcement constitute an offer for securities?

No. The announcement explicitly states it does not constitute, or form part of, an offer or solicitation of an offer for securities.

How many treasury shares does Haleon hold after this transaction?

The company holds 3,880,205 treasury shares following the settlement.